Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
International Journal of Clinical Oncology|March 17, 2021
Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patientsTakayuki Tokunaga, Motohiko Tanaka, Kentaro Tanaka, et al.
Anticancer Research|July 27, 2023
Stent Graft of Pseudoaneurysm Rupture After Subtotal Stomach-preserving PancreaticoduodenectomyKoichi Kimura, Ryosuke Minagawa, Terutoshi Yamaoka, et al.
BMC Gastroenterology|November 10, 2020
Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control studyMasakuni Tateyama, Hideaki Naoe, Motohiko Tanaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 9, 2021
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensityTakayuki Tokunaga, Masakuni Tateyama, Kentaro Tanaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitisHiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto, et al.
Annals of Surgical Oncology|November 2, 2025
The Prognostic Impact of C-Reactive Protein-Albumin-Lymphocyte Index (Cally Index) in Patients with Surgically Resected Non-Small-Cell Lung CancerKazuhiro Mizota, Fumihiko Kinoshita, Bassi Giacomo, et al.
In Vivo (Athens, Greece)|October 30, 2024
Transileocolic Portal Vein Embolization Increases Remnant Liver Volume After Major HepatectomyKoichi Kimura, Ryosuke Minagawa, Terutoshi Yamaoka, et al.
Cancers|March 11, 2023
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular CarcinomaTakayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo, et al.
Biochemical and Biophysical Research Communications|May 27, 2010
Aberrant expression of interferon regulatory factor 3 in human lung cancerTakayuki Tokunaga, Yuki Naruke, Sayuri Shigematsu, et al.
Hepatology Communications|November 27, 2021
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular CarcinomaSatoshi Narahara, Takehisa Watanabe, Katsuya Nagaoka, et al.
Pageof 4